Journal of Pharmacological Sciences, 2007 We examined the pharmacological profile of ramosetron, a 5-HT3-receptor antagonist for irritable bowel syndrome with diarrhea, comparing it with those of other 5-HT3-receptor antagonists, alosetron and cilansetron, and the anti-diarrheal agent loperamide.
Takuya Hirata
exaly +4 more sources
Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis [PDF]
Korean Journal of Anesthesiology, 2011 BackgroundPostoperative nausea and vomiting (PONV) remains a challenge for patients and health professionals despite various newly developed prophylactic interventions.
Won Oak Kim +3 more
doaj +6 more sources
Ramosetron-induced acute dystonic extrapyramidal reactions: A case report [PDF]
Saudi Journal of AnaesthesiaExtrapyramidal symptoms induced by ondansetron, a selective 5-HT3 receptor antagonist, are well-documented. However, reports of similar effects following ramosetron administration are rare.
Eun Kyung Choi +2 more
doaj +5 more sources
Accidental epidural administration of sugammadex and ramosetron - A case report - [PDF]
Anesthesia and Pain MedicineBackground Wrong-route administration of intravenous (IV) medications into the epidural space is a rare but potentially harmful event in anesthetic practice. Although various agents have been inadvertently injected via the epidural route, there have been
Ji Wook Kim, Taek Yong Ko, Donghee Kang
doaj +4 more sources
Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study [PDF]
Dose-ResponseBackground Dexamethasone in conjunction with type 3 serotonin receptor antagonists are being used to the prevention and treatment of chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting in clinic.
Baoxia Fang +3 more
doaj +3 more sources
Cost-effectiveness of prophylactic ramosetron in the prevention of postoperative nausea and vomiting. [PDF]
PLoS ONEObjectivesThis study was conducted to assess the cost-effectiveness of prophylactic use of ramosetron compared to no antiemetic medications for the prevention of postoperative nausea and vomiting (PONV) from the healthcare payer and societal perspectives
David Suh +5 more
doaj +4 more sources
Effects of ramosetron orally disintegrating tablets on the prophylaxis of post-discharge nausea and/or vomiting in female patients undergoing day surgery under general anesthesia: a randomized controlled trial [PDF]
Perioperative Medicine, 2022 Background This study was performed to evaluate the effectiveness of ramosetron orally disintegrating tablets (ODTs) in preventing post-discharge nausea and/or vomiting (PDNV) in female patients following outpatient surgery under general anesthesia ...
Hyun-Jung Shin +7 more
doaj +2 more sources
The Safety and Efficacy of Ramosetron versus Psyllium for the Treatment of Fecal Incontinence (SERAFI): Study protocol for a randomized, parallel, non-inferiority trial [PDF]
TrialsBackground Fecal incontinence (FI) is a prevalent condition affecting 2% to 21% of the general population, with higher rates in older adults and specific settings such as nursing homes and hospitals.
Jesung Park +6 more
doaj +2 more sources
Drug Design, Development and Therapy, 2020 Jingsheng Xia,1 Peng Chen2 1Department of Pharmacy, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, Hubei 430060, People’s Republic of China; 2Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060 ...
Chen Peng
exaly +2 more sources
Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study [PDF]
Obstetrics & Gynecology Science, 2019 ObjectiveThe purpose of this study was to evaluate the effectiveness of scheduled ramosetron injections for controlling postoperative nausea and vomiting (PONV) after single-port access total laparoscopic hysterectomy (SPA-TLH).MethodsNinety patients who
Shoou-Chern Li +6 more
doaj +1 more source